Merck &amp; Co.'s new pain reliever, Arcoxia, was gentler on the stomach than an older pain reliever, the drug maker said as it released results of a new study Tuesday.
Also on Monday, Prudential Equity Group analyst Tim Anderson downgraded the stock's rating to neutral from overweight.
Merck withdrew its Cox-2 drug, Vioxx, from the market last month, citing a study that found it increased the risk of heart attack and stroke after 18 months of use.
Now there are concerns that the entire class of drugs cause similar problems The European Medicines Agency said its review will look at
